Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Gets FDA Approval For Generic Flomax
Flomax is used to treat the symptoms of an enlarged prostate. Flomax doesn’t shrink the prostate. Instead, it relaxes the muscle around it, freeing the flow of urine
Flomax is used to treat the symptoms of an enlarged prostate. Flomax doesn’t shrink the prostate. Instead, it relaxes the muscle around it, freeing the flow of urine
Michael Pearson, chairman and CEO of Valeant Pharma, said: “Combining another dermatology company with the Renaud portfolio we acquired last year is another step in our Canadian strategy.
The new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of
The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings. Results from
Reportedly, Piramal Healthcare is in talks with Sanofi Aventis and Glaxo Smithkline to sell its domestic formulation business which currently contributes 55% of revenues. The acquisition is expected
SCHEMA ST4’s range of application covers such areas as technical documentation, software documentation and help systems, catalogs, labeling for pharmaceutical companies, loose-leaf publications for specialized publishers, contract management
Heplisav is a vaccine designed to protect against hepatitis B infection. The DSMB reviewed safety data from two ongoing multi-center Phase 3 trials evaluating Heplisav, one trial in
Earlier, FDA had granted PrevOnco orphan drug status in August 2008, and in March 2010, additionally, NexMed has filed its investigational new drug (IND) application for the product
PPD posted a net income of $17.2m for the first quarter 2010, or $0.14 per diluted share, compared to $45.14m, or $0.38 per diluted share, for the prior
Boston Scientific has posted a net loss of $1.58bn for the first quarter 2010, or $1.05 per diluted share, compared to $13m, or $0.01 per diluted share, for